TG Therapeutics, Inc. (TGTX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

TG Therapeutics, Inc. (TGTX) Healthcare & Pipeline Overview

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in innovative therapies for B-cell malignancies and autoimmune disorders. With a focus on glycoengineered monoclonal antibodies and oral inhibitors, the company aims to address unmet needs in lymphoma, leukemia, and multiple sclerosis, positioning itself within the competitive biotechnology landscape.

What Is the Investment Thesis for TGTX?

The company's lead product candidates, Ublituximab and Umbralisib, address significant unmet needs in lymphoma, leukemia, and multiple sclerosis. With a market capitalization of $8.38B and a profit margin of 66.0%, TG Therapeutics demonstrates strong financial performance. Growth catalysts include the potential approval and commercialization of Ublituximab for multiple sclerosis and ongoing clinical trials for its other pipeline assets. The company's strategic collaborations and alliances further enhance its growth prospects. However, potential risks include regulatory hurdles, competition from established players, and the inherent uncertainties associated with drug development. The company's P/E ratio of 18.19 suggests a reasonable valuation relative to its earnings, making it an interesting opportunity for investors seeking exposure to the biotechnology sector.

Based on FMP financials and quantitative analysis

TGTX Key Highlights

Market Cap of $8.38B indicates substantial investor confidence in TG Therapeutics' pipeline and market potential.

• Profit Margin of 66.0% showcases the company's ability to generate significant earnings from its revenue streams.
• Gross Margin of 83.0% reflects efficient cost management in the production and distribution of its pharmaceutical products.
• P/E Ratio of 18.19 suggests a potentially undervalued stock compared to its earnings, making it attractive to value investors.
• Beta of 1.75 indicates higher volatility than the market, which may appeal to investors seeking higher returns but also implies greater risk.

Who Are TGTX's Competitors?

TGTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TGTX's Key Strengths?

Innovative pipeline of therapies targeting B-cell malignancies and autoimmune diseases.

• Strong financial performance with high profit and gross margins.
• Strategic collaborations with leading pharmaceutical companies.
• Proprietary drug development platform.

What Are TGTX's Weaknesses?

Reliance on regulatory approvals for pipeline assets.

• Competition from established pharmaceutical giants.
• High beta indicating greater stock volatility.
• Limited product diversification.

What Could Drive TGTX Stock Higher?

Potential regulatory approval of Ublituximab for multiple sclerosis.

• Clinical trial results for Umbralisib in lymphoma treatment.
• Development progress of Cosibelimab for PD-L1 inhibition.
• Expansion of strategic collaborations and licensing agreements.

What Are the Key Risks for TGTX?

Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.

• Regulatory setbacks and clinical trial failures.
• Competition from established pharmaceutical companies.
• Patent expirations and intellectual property challenges.
• High beta indicating greater stock volatility.
• Economic downturns affecting healthcare spending.

What Are the Growth Opportunities for TGTX?

• Expansion of Ublituximab into Multiple Sclerosis Market: Ublituximab, a glycoengineered monoclonal antibody, holds significant potential in the treatment of relapsing forms of multiple sclerosis. The global multiple sclerosis market is projected to reach $30 billion by 2028. Successful clinical trials and regulatory approval could drive substantial revenue growth for TG Therapeutics. The company's differentiated approach with Ublituximab may offer advantages over existing therapies, capturing a significant share of the market.
• Advancement of Umbralisib in Lymphoma Treatment: Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon, targets chronic lymphocytic leukemia (CLL), marginal zone lymphoma, and follicular lymphoma. The lymphoma treatment market is expected to grow to $20 billion by 2027. TG Therapeutics aims to expand the use of Umbralisib through ongoing clinical trials and potential label expansions, addressing unmet needs in specific lymphoma subtypes and driving revenue growth.
• Development of Cosibelimab for PD-L1 Inhibition: Cosibelimab, a human monoclonal antibody targeting PD-L1, presents opportunities in various cancer indications. The PD-1 and PD-L1 inhibitor market is projected to reach $40 billion by 2028. TG Therapeutics is exploring Cosibelimab's potential in combination therapies and specific tumor types, aiming to capture a share of this expanding market. Successful clinical trials and regulatory approvals could establish Cosibelimab as a key growth driver.
• Strategic Collaborations and Licensing Agreements: TG Therapeutics has established collaborations with companies such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., and Ligand Pharmaceuticals Incorporated. These partnerships provide access to novel technologies and expand the company's pipeline. By leveraging these collaborations, TG Therapeutics can accelerate the development of new therapies and diversify its product portfolio, driving long-term growth.
• Expansion into New Therapeutic Areas: TG Therapeutics is exploring preclinical programs targeting BET, interleukin-1 receptor associated kinase-4, and GITR. These programs represent opportunities to expand the company's focus beyond B-cell malignancies and autoimmune diseases. By diversifying its therapeutic focus, TG Therapeutics can mitigate risks associated with its core pipeline and capitalize on emerging opportunities in other disease areas. Successful development of these preclinical programs could unlock new growth avenues for the company.

What Are TGTX's Competitive Advantages?

• Proprietary drug development platform for creating novel therapies.
• Strong intellectual property portfolio protecting its key assets.
• Strategic collaborations with leading pharmaceutical companies.
• Established expertise in B-cell malignancies and autoimmune diseases.

What Does TGTX Do?

TG Therapeutics, Inc., incorporated in 1993 and headquartered in New York, is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's primary focus is on addressing unmet medical needs through innovative therapies. Its lead product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody, which is being explored for the treatment of B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis. Additionally, TG Therapeutics is developing Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon, targeting CLL, marginal zone lymphoma, and follicular lymphoma. Beyond these core assets, TG Therapeutics is also advancing Cosibelimab, a human monoclonal antibody targeting programmed death-ligand 1 (PD-L1), and TG-1701, an orally available Bruton's tyrosine kinase (BTK) inhibitor. The company's pipeline extends to preclinical programs targeting BET, interleukin-1 receptor associated kinase-4, and GITR. TG Therapeutics has established strategic collaborations with companies such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys, as well as alliances with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A. These partnerships support the company's research and development efforts and expand its therapeutic reach. TG Therapeutics operates with 352 employees and is committed to delivering innovative solutions for patients with B-cell malignancies and autoimmune diseases.

What Products and Services Does TGTX Offer?

• Develops and commercializes novel treatments for B-cell malignancies.
• Focuses on therapies for autoimmune diseases.
• Creates glycoengineered monoclonal antibodies like Ublituximab.
• Develops oral inhibitors such as Umbralisib.
• Targets conditions like non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL).
• Develops treatments for relapsing forms of multiple sclerosis.
• Creates human monoclonal antibodies like Cosibelimab.

How Does TGTX Make Money?

• Develops pharmaceutical products through internal research and development.
• Out-licenses certain technologies and programs to other companies.
• Generates revenue through the sale of approved pharmaceutical products.
• Forms strategic alliances and collaborations to expand its pipeline.

What Industry Does TGTX Operate In?

TG Therapeutics operates within the biotechnology industry, a sector characterized by rapid innovation and intense competition. The market for B-cell malignancy and autoimmune disease treatments is substantial and growing, driven by an aging population and increasing prevalence of these conditions. The company competes with established pharmaceutical giants and other emerging biotech firms, all vying for market share. TG Therapeutics' focus on novel therapies, such as glycoengineered monoclonal antibodies and oral inhibitors, positions it to capitalize on the demand for more effective and targeted treatments. The biotechnology industry is subject to stringent regulatory oversight and faces challenges related to clinical trial success and market access.

Who Are TGTX's Key Customers?

• Patients suffering from B-cell malignancies.
• Patients with autoimmune diseases.
• Hospitals and clinics that administer the company's therapies.
• Specialty pharmacies that distribute the company's products.

TG Therapeutics, Inc. Financial Trajectory

TG Therapeutics, Inc. (TGTX) reported $240.3M in revenue for Q2 FY2026, reflecting 17.3% growth compared to the prior quarter. The company recorded net income of $7.8M, with diluted EPS of $0.05. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, TGTX averaged $0.69 in diluted EPS.

Company Profile

TG Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Morrisville, US. The company is led by CEO Michael S. Weiss. TGTX has traded publicly since 2010.

How TG Therapeutics, Inc. Is Valued

TG Therapeutics, Inc. carries a market capitalization of $8.38B, placing it in the mid-cap category. Analyst price targets span from $78.00 to $83.00, with a consensus of $80.50. At the current price of $54.74, that implies approximately 47% upside potential. Relative to its peer group, TGTX's quantitative score of 66/100 is roughly in line with the peer average of 68/100.

Return on equity for TG Therapeutics, Inc. stands at 72.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 26.9%, showing how much profit it generates from its asset base. TGTX trades at a trailing price-to-earnings ratio of 18.19, below the Healthcare sector average of ~21.50x. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.3%, the inverse of the P/E and a quick read on earnings relative to price.

TG Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.41 places it in the safe zone, indicating low near-term bankruptcy risk.

TG Therapeutics, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 81.7% above estimates on average.

Over the past six months, TG Therapeutics, Inc. insiders filed 8 SEC Form 4 transactions — 3 sales and 5 purchases. On net that is roughly 36K shares acquired (about $0) — insiders putting money in tends to read as conviction.

TGTX Financials

TGTX Latest News

TGTX Analyst Consensus

TGTX MoonshotScore

Latest TG Therapeutics, Inc. Analysis

What Investors Ask About TG Therapeutics, Inc. (TGTX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources